7,572.40

+31.00

+0.41%

51,795.48

-188.50

-0.36%

25,352.69

+188.32

+0.75%

2,827.69

+21.81

+0.78%

4.9580

+0.0640

+1.31%

20.54

-0.61

-2.89%

3,937.60

-32.00

-0.81%

77,616.10

+219.54

+0.28%

Crude Oil Dec 26

96.42

-0.04

-0.04%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGS - Nasdaq Real Time Price USD

First Tracks Biotherapeutics, Inc. (TRAX)

45.96 +0.91 (+2.02%)

As of 10:42:06 AM EST. Market Open.

Loading Chart for TRAX

Chart Range Bar

Interval:

In partnership with ChartIQ

First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics Announces $200 Million Private Placement

7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data

7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data

First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data

First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data

First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results

First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results

First Tracks climbs on ‘impressive’ celiac study data

First Tracks climbs on ‘impressive’ celiac study data

Why This IPO Stock, An AnaptysBio Spinoff, Just Surged

Why This IPO Stock, An AnaptysBio Spinoff, Just Surged

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results

First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results

Why Is First Tracks Biotherapeutics Stock Soaring Monday?

Why Is First Tracks Biotherapeutics Stock Soaring Monday?

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: